HESTERBIO vs THEMISMED: Stock Comparison

Hester Biosciences Limited vs Themis Medicare Limited

Live data: 22 July 2026, 3:01 PM IST • Source: NSE and company filings

Hester Biosciences Limited is the larger company by market capitalisation. Hester Biosciences Limited shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Hester Biosciences Limited and Themis Medicare Limited on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, HESTERBIO is more favourable on 12 of 13 scored metrics and THEMISMED on 1These counts are context-free and are not an overall rating.

Key Differences

Market Cap
HESTERBIO is the larger company
₹2,068 Cr vs ₹1,004 Cr
P/E Ratio
HESTERBIO has a lower P/E
37.48x vs 938.33x
P/B Ratio
THEMISMED has a lower P/B
2.6x vs 5.79x
EPS
HESTERBIO has higher earnings per share
₹65.36 vs ₹0.12
Dividend Yield
HESTERBIO has a higher dividend yield
0.44% vs 0.43%
Revenue Growth (TTM YoY)
HESTERBIO has faster revenue growth
38.2% vs 6.7%
EPS Growth (TTM YoY)
HESTERBIO has faster EPS growth
968.7% vs 0%
Qtr Sales Growth
HESTERBIO has stronger quarterly sales growth
22.2% vs 6.74%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricHESTERBIOTHEMISMED
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricHESTERBIOTHEMISMED
Live Price₹2,432.1₹108.4
Day Change-0.73%-3.52%
Volume6,19570,771
52-Week High₹2,660₹148
52-Week Low₹1,239.3₹64.95
Distance from 52W High-8.57%-26.76%

Valuation

MetricHESTERBIOTHEMISMED
Market Cap₹2,068 Cr₹1,004 Cr
P/E Ratio37.48x938.33x
P/B Ratio5.79x2.6x
EPS₹65.36₹0.12
Book Value₹423.46₹43.06
Dividend Yield0.44%0.43%

Growth

MetricHESTERBIOTHEMISMED
Revenue Growth (TTM YoY)38.2%6.7%
EPS Growth (TTM YoY)968.7%0%
Qtr Sales Growth22.2%6.74%
Qtr Profit Growth993%192%

Profitability & Leverage

MetricHESTERBIOTHEMISMED
ROE15.9%0.29%
ROCE15.2%2.74%
Net Margin16.73%0.33%
Operating Margin26.1%-2.9%
Debt to Equity0.54x25.11x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricHESTERBIOTHEMISMED
Promoter Holding44.28%57.5%
FII Holding0.31% 0.07 pp0.11% 0.06 pp
DII Holding0%0.01%
Public Holding45.95% 0.06 pp32.78% 0.05 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Hester Biosciences Limited and Themis Medicare Limited.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.